A citation-based method for searching scientific literature

Cara E Toscan, Duohui Jing, Chelsea Mayoh, Richard B Lock. Br J Cancer 2020
Times Cited: 5







List of co-cited articles
16 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance.
Guo Wei, David Twomey, Justin Lamb, Krysta Schlis, Jyoti Agarwal, Ronald W Stam, Joseph T Opferman, Stephen E Sallan, Monique L den Boer, Rob Pieters,[...]. Cancer Cell 2006
379
60

CRLF2 rearrangement in Ph-like acute lymphoblastic leukemia predicts relative glucocorticoid resistance that is overcome with MEK or Akt inhibition.
Lauren K Meyer, Cristina Delgado-Martin, Shannon L Maude, Kevin M Shannon, David T Teachey, Michelle L Hermiston. PLoS One 2019
8
40

Relapse-associated AURKB blunts the glucocorticoid sensitivity of B cell acute lymphoblastic leukemia.
Coralie Poulard, Hye Na Kim, Mimi Fang, Karina Kruth, Celine Gagnieux, Daniel S Gerke, Deepa Bhojwani, Yong-Mi Kim, Martin Kampmann, Michael R Stallcup,[...]. Proc Natl Acad Sci U S A 2019
20
40

Glucocorticoid use in acute lymphoblastic leukaemia.
Hiroto Inaba, Ching-Hon Pui. Lancet Oncol 2010
211
40

Glucocorticoid resistance in paediatric acute lymphoblastic leukaemia.
Vivek A Bhadri, Toby N Trahair, Richard B Lock. J Paediatr Child Health 2012
42
40

Glucocorticoid-resistant B cell acute lymphoblastic leukemia displays receptor tyrosine kinase activation.
Rohit A Chougule, Kinjal Shah, Sausan A Moharram, Johan Vallon-Christersson, Julhash U Kazi. NPJ Genom Med 2019
10
40

MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia.
K Canté-Barrett, J A P Spijkers-Hagelstein, J G C A M Buijs-Gladdines, J C M Uitdehaag, W K Smits, J van der Zwet, R C Buijsman, G J R Zaman, R Pieters, J P P Meijerink. Leukemia 2016
65
40


Suppression of B-cell development genes is key to glucocorticoid efficacy in treatment of acute lymphoblastic leukemia.
Karina A Kruth, Mimi Fang, Dawne N Shelton, Ossama Abu-Halawa, Ryan Mahling, Hongxing Yang, Jonathan S Weissman, Mignon L Loh, Markus Müschen, Sarah K Tasian,[...]. Blood 2017
32
40

Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia.
Erich Piovan, Jiyang Yu, Valeria Tosello, Daniel Herranz, Alberto Ambesi-Impiombato, Ana Carolina Da Silva, Marta Sanchez-Martin, Arianne Perez-Garcia, Isaura Rigo, Mireia Castillo,[...]. Cancer Cell 2013
174
40

Glucocorticoid resistance in T-lineage acute lymphoblastic leukaemia is associated with a proliferative metabolism.
A H Beesley, M J Firth, J Ford, R E Weller, J R Freitas, K U Perera, U R Kees. Br J Cancer 2009
54
40

Opposing regulation of BIM and BCL2 controls glucocorticoid-induced apoptosis of pediatric acute lymphoblastic leukemia cells.
Duohui Jing, Vivek A Bhadri, Dominik Beck, Julie A I Thoms, Nurul A Yakob, Jason W H Wong, Kathy Knezevic, John E Pimanda, Richard B Lock. Blood 2015
79
40

Acute lymphoblastic leukemia: a comprehensive review and 2017 update.
T Terwilliger, M Abdul-Hay. Blood Cancer J 2017
463
40

Glucocorticoids paradoxically facilitate steroid resistance in T cell acute lymphoblastic leukemias and thymocytes.
Lauren K Meyer, Benjamin J Huang, Cristina Delgado-Martin, Ritu P Roy, Aaron Hechmer, Anica M Wandler, Tiffaney L Vincent, Paolo Fortina, Adam B Olshen, Brent L Wood,[...]. J Clin Invest 2020
25
40


Tumor suppressor IKZF1 mediates glucocorticoid resistance in B-cell precursor acute lymphoblastic leukemia.
R Marke, J Havinga, J Cloos, M Demkes, G Poelmans, L Yuniati, D van Ingen Schenau, E Sonneveld, E Waanders, R Pieters,[...]. Leukemia 2016
44
40

FDA approves first-in-class SYK inhibitor.
Asher Mullard. Nat Rev Drug Discov 2018
11
20

Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk.
M Turner, P J Mee, P S Costello, O Williams, A A Price, L P Duddy, M T Furlong, R L Geahlen, V L Tybulewicz. Nature 1995
627
20

Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma.
Binu K Sasi, Claudio Martines, Elena Xerxa, Fabiola Porro, Hilal Kalkan, Rosa Fazio, Sven Turkalj, Engin Bojnik, Beata Pyrzynska, Joanna Stachura,[...]. Leukemia 2019
21
20

The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia.
Yair Herishanu, Patricia Pérez-Galán, Delong Liu, Angélique Biancotto, Stefania Pittaluga, Berengere Vire, Federica Gibellini, Ndegwa Njuguna, Elinor Lee, Lawrence Stennett,[...]. Blood 2011
611
20


A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor.
Russell T Burke, Sarah Meadows, Marc M Loriaux, Kevin S Currie, Scott A Mitchell, Patricia Maciejewski, Astrid S Clarke, Julie A Dipaolo, Brian J Druker, Brian J Lannutti,[...]. Oncotarget 2014
52
20

Therapeutic potential of spleen tyrosine kinase inhibition for treating high-risk precursor B cell acute lymphoblastic leukemia.
Tatiana Perova, Ildiko Grandal, Lauryl M J Nutter, Eniko Papp, Irina R Matei, Joseph Beyene, Paul E Kowalski, Johann K Hitzler, Mark D Minden, Cynthia J Guidos,[...]. Sci Transl Med 2014
27
20

The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
Sabine Ponader, Shih-Shih Chen, Joseph J Buggy, Kumudha Balakrishnan, Varsha Gandhi, William G Wierda, Michael J Keating, Susan O'Brien, Nicholas Chiorazzi, Jan A Burger. Blood 2012
489
20

Syk tyrosine kinase required for mouse viability and B-cell development.
A M Cheng, B Rowley, W Pao, A Hayday, J B Bolen, T Pawson. Nature 1995
545
20

The future of B-cell lymphoma therapy: the B-cell receptor and its downstream pathways.
Vaishalee P Kenkre, Brad S Kahl. Curr Hematol Malig Rep 2012
18
20

Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition.
S Köhrer, O Havranek, F Seyfried, C Hurtz, G P Coffey, E Kim, E Ten Hacken, U Jäger, K Vanura, S O'Brien,[...]. Leukemia 2016
49
20

SLP-65 regulates immunoglobulin light chain gene recombination through the PI(3)K-PKB-Foxo pathway.
Sebastian Herzog, Eva Hug, Sonja Meixlsperger, Ji-Hye Paik, Ronald A DePinho, Michael Reth, Hassan Jumaa. Nat Immunol 2008
118
20


Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia.
Anjali Cremer, Jana M Ellegast, Gabriela Alexe, Elizabeth S Frank, Linda Ross, S Haihua Chu, Yana Pikman, Amanda Robichaud, Amy Goodale, Björn Häupl,[...]. Cancer Discov 2020
16
20

Role of Syk in B-cell development and antigen-receptor signaling.
R J Cornall, A M Cheng, T Pawson, C C Goodnow. Proc Natl Acad Sci U S A 2000
87
20

3
33

SYK inhibition thwarts the BAFF - B-cell receptor crosstalk and thereby antagonizes Mcl-1 in chronic lymphocytic leukemia.
Cody Paiva, Taylor A Rowland, Bhargava Sreekantham, Claire Godbersen, Scott R Best, Prabhjot Kaur, Marc M Loriaux, Stephen E F Spurgeon, Olga V Danilova, Alexey V Danilov. Haematologica 2017
18
20

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Jonathan W Friedberg, Jeff Sharman, John Sweetenham, Patrick B Johnston, Julie M Vose, Ann Lacasce, Julia Schaefer-Cutillo, Sven De Vos, Rajni Sinha, John P Leonard,[...]. Blood 2010
589
20

BLNK mediates Syk-dependent Btk activation.
Y Baba, S Hashimoto, M Matsushita, D Watanabe, T Kishimoto, T Kurosaki, S Tsukada. Proc Natl Acad Sci U S A 2001
104
20

The SYK tyrosine kinase: a crucial player in diverse biological functions.
Attila Mócsai, Jürgen Ruland, Victor L J Tybulewicz. Nat Rev Immunol 2010
815
20

Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia.
Maike Buchner, Simon Fuchs, Gabriele Prinz, Dietmar Pfeifer, Kilian Bartholomé, Meike Burger, Nina Chevalier, Laurent Vallat, Jens Timmer, John G Gribben,[...]. Cancer Res 2009
138
20

Effects of common cancer mutations on stability and DNA binding of full-length p53 compared with isolated core domains.
Hwee Ching Ang, Andreas C Joerger, Sebastian Mayer, Alan R Fersht. J Biol Chem 2006
104
20

Antigen receptor tail clue.
M Reth. Nature 1989
20

Fiji: an open-source platform for biological-image analysis.
Johannes Schindelin, Ignacio Arganda-Carreras, Erwin Frise, Verena Kaynig, Mark Longair, Tobias Pietzsch, Stephan Preibisch, Curtis Rueden, Stephan Saalfeld, Benjamin Schmid,[...]. Nat Methods 2012
20


Structural and biophysical characterization of the Syk activation switch.
Ulrich Grädler, Daniel Schwarz, Verena Dresing, Djordje Musil, Jörg Bomke, Matthias Frech, Hartmut Greiner, Stefan Jäkel, Thomas Rysiok, Dirk Müller-Pompalla,[...]. J Mol Biol 2013
55
20

Gain of function of mutant p53 by coaggregation with multiple tumor suppressors.
Jie Xu, Joke Reumers, José R Couceiro, Frederik De Smet, Rodrigo Gallardo, Stanislav Rudyak, Ann Cornelis, Jef Rozenski, Aleksandra Zwolinska, Jean-Christophe Marine,[...]. Nat Chem Biol 2011
347
20

An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia.
Jeff Sharman, Michael Hawkins, Kathryn Kolibaba, Michael Boxer, Leonard Klein, Meihua Wu, Jing Hu, Steve Abella, Chris Yasenchak. Blood 2015
132
20

SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma.
Linfeng Chen, Stefano Monti, Przemyslaw Juszczynski, John Daley, Wen Chen, Thomas E Witzig, Thomas M Habermann, Jeffery L Kutok, Margaret A Shipp. Blood 2008
244
20

Cutting edge: constitutive B cell receptor signaling is critical for basal growth of B lymphoma.
Murali Gururajan, C Darrell Jennings, Subbarao Bondada. J Immunol 2006
85
20

Mutational landscape and significance across 12 major cancer types.
Cyriac Kandoth, Michael D McLellan, Fabio Vandin, Kai Ye, Beifang Niu, Charles Lu, Mingchao Xie, Qunyuan Zhang, Joshua F McMichael, Matthew A Wyczalkowski,[...]. Nature 2013
20

Rationale for targeting BCL6 in MLL-rearranged acute lymphoblastic leukemia.
Christian Hurtz, Lai N Chan, Huimin Geng, Erica Ballabio, Gang Xiao, Gauri Deb, Haytham Khoury, Chun-Wei Chen, Scott A Armstrong, Jianjun Chen,[...]. Genes Dev 2019
9
20

NIH Image to ImageJ: 25 years of image analysis.
Caroline A Schneider, Wayne S Rasband, Kevin W Eliceiri. Nat Methods 2012
20

A PREVIOUSLY UNKNOWN UNIQUE CHALLENGE FOR INHIBITORS OF SYK ATP-BINDING SITE: ROLE OF SYK AS A CELL CYCLE CHECKPOINT REGULATOR.
Fatih M Uckun, Hong Ma, Zahide Ozer, Patricia Goodman, Jian Zhang, Sanjive Qazi. EBioMedicine 2014
8
20


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.